Biopharmaceutical company Kite, part of Gilead Sciences Inc (Nasdaq:GILD), on Thursday announced a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology firm developing in vivo CAR therapeutics, for USD350m in cash.

The transaction remains subject to regulatory clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

This acquisition brings Kite a novel in vivo platform designed to generate CAR T-cells directly within patients. Unlike traditional CAR T therapies that require harvesting and reinfusion, Interius's approach enables delivery via a single intravenous infusion without preconditioning chemotherapy or complex cell processing.

Kite stated that in vivo therapy could make cell therapy more accessible and scalable, offering new options for patients with rapidly progressing disease. Interius's modular platform architecture allows rapid adaptation across multiple indications and manufacturing scales.

Upon closing, Interius's team and operations will integrate into Kite's research organisation, establishing a centre of excellence in Philadelphia.

Gilead expects the acquisition to reduce its 2025 GAAP and non-GAAP earnings per share by approximately USD0.23 to USD0.25.